ES2262221T3 - Compuestos de tetraciclina para el tratamiento de ciertos tipos de cancer. - Google Patents

Compuestos de tetraciclina para el tratamiento de ciertos tipos de cancer.

Info

Publication number
ES2262221T3
ES2262221T3 ES98902437T ES98902437T ES2262221T3 ES 2262221 T3 ES2262221 T3 ES 2262221T3 ES 98902437 T ES98902437 T ES 98902437T ES 98902437 T ES98902437 T ES 98902437T ES 2262221 T3 ES2262221 T3 ES 2262221T3
Authority
ES
Spain
Prior art keywords
cmt
dimethylamino
tetracycline
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98902437T
Other languages
English (en)
Spanish (es)
Inventor
Lorne M. Golub
Thomas F. Mcnamara
Nungavaram S. Ramamurthy
Hsi-Ming Lee
Sanford Simon
Balakrishna L. Lokeshwar
Marie G. Selzer
Normal L. Block
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Research Foundation of the State University of New York
Original Assignee
University of Miami
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami, Research Foundation of the State University of New York filed Critical University of Miami
Application granted granted Critical
Publication of ES2262221T3 publication Critical patent/ES2262221T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES98902437T 1997-01-15 1998-01-15 Compuestos de tetraciclina para el tratamiento de ciertos tipos de cancer. Expired - Lifetime ES2262221T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US783655 1997-01-15
US08/783,655 US5837696A (en) 1997-01-15 1997-01-15 Method of inhibiting cancer growth

Publications (1)

Publication Number Publication Date
ES2262221T3 true ES2262221T3 (es) 2006-11-16

Family

ID=25130005

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98902437T Expired - Lifetime ES2262221T3 (es) 1997-01-15 1998-01-15 Compuestos de tetraciclina para el tratamiento de ciertos tipos de cancer.

Country Status (11)

Country Link
US (2) US5837696A (enExample)
EP (1) EP0971585B1 (enExample)
JP (1) JP4428727B2 (enExample)
KR (1) KR20000070212A (enExample)
AT (1) ATE321452T1 (enExample)
AU (1) AU729886B2 (enExample)
CA (1) CA2277865C (enExample)
DE (1) DE69834024T2 (enExample)
ES (1) ES2262221T3 (enExample)
PT (1) PT971585E (enExample)
WO (1) WO1998031224A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837696A (en) * 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US6429204B1 (en) 1997-01-15 2002-08-06 University Of Miami Method of inhibiting cancer growth
DK1041991T3 (da) * 1997-12-19 2008-07-28 Univ New York Ikke-antibakterielle tetracycliner til behandling af multipel sklerose
US6277061B1 (en) * 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) * 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) * 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
WO2000038715A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6984619B1 (en) * 1999-03-19 2006-01-10 Arch Development Corporation Method for protection against tumor metastasis formation
DE10032256C2 (de) * 2000-07-03 2003-06-05 Infineon Technologies Ag Chip-ID-Register-Anordnung
CA2447008A1 (en) * 2001-04-05 2002-10-24 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
EP1408987B1 (en) 2001-07-13 2013-04-10 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
WO2003030819A2 (en) * 2001-10-05 2003-04-17 Tetragenex Pharmaceuticals, Inc. Tetracycline derivatives and methods of use thereof
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
EP2311797A1 (en) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
JP2005526754A (ja) 2002-03-08 2005-09-08 パラテック ファーマシューティカルズ インコーポレイテッド アミノメチル置換されたテトラサイクリン化合物
EP1503981A4 (en) 2002-03-21 2007-08-15 Paratek Pharm Innc SUBSTITUTED TETRACYCLINE COMPOUNDS
WO2003092629A2 (en) * 2002-05-06 2003-11-13 Collagenex Pharmaceuticals, Inc. Methods of simultaneously treating mucositis and fungal infection
EP1505961A4 (en) * 2002-05-20 2009-09-02 Collagenex Pharm Inc METHOD FOR TREATING ALLERGIC REACTIONS
WO2004006850A2 (en) 2002-07-12 2004-01-22 Paratek Pharmaceuticals, Inc 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS
JP4686189B2 (ja) * 2002-10-24 2011-05-18 パラテック ファーマシューティカルズ インコーポレイテッド Ｒｎａを調節するための置換テトラサイクリン化合物の使用方法
CA2521885C (en) * 2003-04-07 2013-06-25 Shire Laboratories, Inc. Once daily formulations of tetracyclines
JP4738333B2 (ja) 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド ９−アミノメチルテトラサイクリン化合物のプロドラッグ
WO2005009943A2 (en) 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
EP2332904A3 (en) * 2004-01-15 2012-04-11 Paratek Pharmaceuticals, Inc. Derivatives of tetracycline compounds
WO2006047756A2 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
JP2008518025A (ja) 2004-10-25 2008-05-29 パラテック ファーマシューティカルズ インコーポレイテッド ４−アミノテトラサイクリンおよびその使用の方法
CA2616224A1 (en) * 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
PL2120963T3 (pl) 2006-12-21 2019-05-31 Paratek Pharm Innc Podstawione związki tetracyklinowe do leczenia zaburzeń zapalnych skóry
IL270446B2 (en) * 2006-12-21 2023-10-01 Paratek Pharm Innc A tetracycline compound, a pharmaceutical preparation containing the tetracycline compound, and the tetracycline compound or the pharmaceutical preparation for the treatment of the tetracycline-responsive condition
EP2144870A2 (en) * 2007-04-27 2010-01-20 Paratek Pharmaceuticals, Inc. Methods for synthesizing and purifying aminoalkyl tetracycline compounds
WO2009009042A1 (en) * 2007-07-06 2009-01-15 Paratek Pharmaceuticals, Inc. Methods for synthesizing substituted tetracycline compounds
TWI585071B (zh) 2008-05-19 2017-06-01 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
HUE026562T2 (hu) 2008-08-08 2016-06-28 Tetraphase Pharmaceuticals Inc C7-fluor-helyettesített tetraciklin vegyületek
CN102459153A (zh) 2009-05-08 2012-05-16 四相制药公司 四环素类化合物
EP2470500B1 (en) 2009-08-28 2017-10-04 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
US20120329761A1 (en) * 2010-03-10 2012-12-27 University Health Network Use of tigecycline for treatment of cancer
WO2011123536A1 (en) 2010-03-31 2011-10-06 Tetraphase Pharmaceuticals, Inc. Polycyclic tetracycline compounds
TR201902057T4 (tr) 2012-08-31 2019-03-21 Tetraphase Pharmaceuticals Inc Tetrasiklin bileşikleri.
CA2898113C (en) * 2013-01-14 2022-05-31 Health Clinics Limited Combination cancer therapeutics and uses thereof
MA46567A (fr) 2016-10-19 2019-08-28 Tetraphase Pharmaceuticals Inc Formes cristallines de l'éravacycline
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
WO2020097450A1 (en) 2018-11-09 2020-05-14 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a compound and uses thereof
CN115006411A (zh) * 2022-07-26 2022-09-06 中南大学湘雅医院 依拉环素类化合物的应用、药物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3016587B2 (ja) * 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5308839A (en) * 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
AU1411992A (en) * 1991-01-15 1992-08-27 Robert A Bok A composition containing a tetracycline and use for inhibiting angiogenesis
US5668122A (en) * 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
US5563130A (en) * 1994-12-13 1996-10-08 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5567693A (en) * 1994-12-13 1996-10-22 American Cyanamid Company Method for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5574026A (en) * 1994-12-13 1996-11-12 American Cyanamid Company Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
US5837696A (en) * 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth

Also Published As

Publication number Publication date
ATE321452T1 (de) 2006-04-15
WO1998031224A1 (en) 1998-07-23
DE69834024T2 (de) 2006-12-07
JP4428727B2 (ja) 2010-03-10
AU729886B2 (en) 2001-02-15
AU5910498A (en) 1998-08-07
EP0971585B1 (en) 2006-03-29
KR20000070212A (ko) 2000-11-25
DE69834024D1 (de) 2006-05-18
CA2277865A1 (en) 1998-07-23
JP2001508794A (ja) 2001-07-03
EP0971585A4 (en) 2001-01-24
PT971585E (pt) 2006-08-31
US5837696A (en) 1998-11-17
US6100248A (en) 2000-08-08
CA2277865C (en) 2009-06-02
EP0971585A1 (en) 2000-01-19

Similar Documents

Publication Publication Date Title
AU729886B2 (en) Method of inhibiting cancer growth
AU748870B2 (en) Method of inhibiting membrane-type matrix metalloproteinase
Seftor et al. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis
ES2237945T3 (es) Combinacion de bisfosfonato y tetraciclina.
US6429204B1 (en) Method of inhibiting cancer growth
ES2258854T3 (es) Uso de derivados de tetraciclina para potenciar la produccion de interleucina 10.
ES2258566T3 (es) Combinaciones de farmacos (por ejemplo, clorpromacina y pentamidina) para el tratamiento de trastornos neoplasicos.
US8603506B2 (en) Methods of treating acne
ES2290983T3 (es) Composiciones farmaceuticas que contienen quinazolinona para prevenir neovascularizacion y para tratar malignidades.
CA2323863C (en) Methods and compositions for treating and preventing mucositis
ES2241124T3 (es) Actividad inhibidora de serin-proteinasa mediante tetraciclina hidrofoba.
ES2255107T3 (es) Fomento de la cicatrizacion de heridas mediante tetraciclinas modificadas quimicamente.
EP0586020A1 (en) Tetracyclines alone or in combination with NSAID for treating tissue destruction
CA2440472C (en) Methods of treating acne
ES2310018T3 (es) Tetraciclinas no antibacterianas para el tratamiento de la esclerosis multiple.
EP2258373A1 (en) Composition comprising taurolidine and/or taurultam for the treatment of cancer
Seftor et al. Application of chemically modified tetracyclines (CMTs) in experimental models of cancer and arthritis
MXPA99006554A (en) Method of inhibiting cancer growth
O’Byrne et al. Tumour angiogenesis: a novel therapeutic target in patients with malignant disease
US8030301B2 (en) Treatment of cancers with methylol-containing compounds and at least one electrolyte
US20060199811A1 (en) Method of treatment for preventing or reducing tumor growth in the liver of patient
Brown Matrix Metalloproteinase Inhibitors
NZ522733A (en) Non-antibacterial tetracycline as anti-fungal agents
IE911519A1 (en) A Novel Anti-Collagenolytic Formulation for the Treatment of¹Chronic Inflammatory Diseases